DOI: https://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20220150
Published: 2022-02-24

Combination of systemic terbinafine (250 mg) twice daily and itraconazole (100 mg) twice in a pulse dose in resistant tinea infection

Farhana R. Shumi, Sarker M. A. Shamim, Rabeya Afroz, Shumana Sharmin, Sharmin Kabir, Fahima Mumtaz

Abstract


Background: The management of tinea is challenging in Bangladesh and there are reports of using systemic antifungals at higher doses. The aim of the study was to find out the effectiveness of systemic terbinafine (250 mg) twice daily and itraconazole (100 mg) twice in a pulse dose in resistant tinea infection.

Methods: It was a prospective, observational study conducted in the department of dermatology and venereology, Dhaka Dermatology Institute, Dhaka, Bangladesh from November 2020 to October 2021. Clinically confirmed cases of tinea corporis et cruris were recruited by random sampling techniques for the study and followed up for 12 weeks, till the completion of their treatment. Patients who were pregnant, lactating, non-consensual, as well as those who had a history of anti-mycotic treatment within 2 weeks prior to baseline visit were excluded from the study.

Results: A total of 30 patients were randomly assigned treatment and included in the study. According to within 4 weeks 11 (36.33%) patients were significantly improved and 19 (63.33%) patients were non-significantly improved, >4 week to till 8 weeks 16 (84.21%) patients were improved significantly and 3 (15.79%) patients were improved non-significantly and >8 week to till 12 weeks 3 (100%) patients were improved properly. Mycological cure was achieved in 25 (82.89%) patients, clinical cure rate was achieved same in 24 (79%) patients and complete cure rate was achieved 30 (100%) patients.

Conclusions: The combination of systemic terbinafine (250 mg) twice daily and itraconazole (100 mg) twice in a pulse dose therapy may be an effective and safe therapeutic strategy in the management of registrant tinea infection.


Keywords


Terbinafine, Itraconazole, Antifungal, Resistant, Tinea

Full Text:

PDF

References


Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51:2-15.

Ajello L. Geographic distribution and prevalence of the dermatophytes. Ann NY Acad Sci. 1960;89:30-8.

Verma S, Madhu R. The great Bangladeshn epidemic of superficial tinea infection: an appraisal. Bangladeshn J Dermatol. 2017;62:227-36.

Inamadar AC, Shivanna R. Clinical failure of antifungal therapy of dermatophytoses: Recurrence, resistance, and remedy. Bangladeshn J Drugs Dermatol. 2017;3(1):1-3.

Bishnoi A, Vinay K, Dogra S. Emergence of recalcitrant tinea infection in Bangladesh. Lancet Infect Dis. 2018;18(3):250-1.

Garodia N, Doncker PD, Pande S, Richarz U. Itraconazole: What clinicians should know? Bangladeshn J Drugs Dermatol. 2017;3(1):4-10.

Panda S, Verma S. The menace of tinea infection in Bangladesh: The evidence that we need. Bangladeshn J Dermatol Venereol Leprol. 2017;83(3):281-4.

Johnson MD, Dougall CM, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination Antifungal Therapy. Antimicrob Agents Chemother. 2004;48(3):693-715.

Mahajan R, Sahoo AK. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Bangladeshn Dermatol Online J. 2016;7(2):77-86.

Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert Consensus on The Management of Tinea infection in Bangladesh (ECTODERM Bangladesh). BMC Dermatol. 2018;18(1):6.

Abdel-Rahman S, Newland JG. Update on terbinafine with a focus on dermatophytoses. Clin Cosmet Investig Dermatol. 2009;2:49-63.

McClellan KJ, Wiseman LR, Markham A. Terbinafine. Drugs. 1999;58(1):179-202.

Osborne CS, Leitner I, Favre B, Ryder NS. Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine. Antimicrob Agents Chemothe. 2005;49(7):2840-4.

Sheikh G, Majid I, Kanth F, Hakak R. Relapse after oral terbinafine therapy in tinea infection: A clinical and mycological study. Bangladeshn J Dermatol. 2016;61(5):529-33.

Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B, et al. Efficacy and safety of terbinafine 500 mg once daily in patients with tinea infection. Bangladeshn J Dermatol. 2017;62(4):395-9.

Shakya N, Jha S, Dangol A, Shakya S, Shah A. Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris. Med J Shree Birendra Hospital. 2013;11(1):24-6.

Chow KW, Ting HC, Yap YP, Yee KC, Purushotaman A, Subramanian S, et al. Short treatment schedules of itraconazole in tinea infection. Int J Dermatol. 1998;37(6):446-8.

Rohatgi S, Ardeshna KP, Jerajani HR. Successful treatment of recurrent tinea infection with isotretinoin and itraconazole. Bangladeshn J Dermatol, Venereol, Leprol. 2016;82(5):579-82.

Markus A. Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Berlin: Springer-Verlag. 1999;1-10.

Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010;70:2133-52.

Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin – A prospective, randomized comparative study. Bangladeshn J Pharmacol. 2019;51(2):116-9.

Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of tinea infection. J Dermatol Treat. 2020;31(7):749-53.

Ellis D, Watson A. Systemic antifungal agents for cutaneous fungal infections. Aust Prescr. 1996;19(3):72-5.

Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 1998;37(9):703-5.

Rengasamy M, Chellam J, Ganapati S. Systemic therapy of tinea infection: Practical and systematic approach. Clin Dermatol Rev. 2017;1(3):19-23.

Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS, et al. Biological, Biochemical, and Molecular Characterization of a New Clinical Trichophyton rubrum Isolate Resistant to Terbinafine. Aust Agents Chemother. 2006;50(6):2234-6.

Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA, et al. Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine. Antimicrob Agents Chemother. 2003;47(1):82-6.

Hosseini-Yeganeh M, McLachlan AJ. Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans. Antimicrob Agents Chemoth. 2002;46(7):2219-28.

Cole GW. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol. 1989;125(11):1537-9.

Hay RJ, Logan RA, Moore MK, Midgely G, Clayton YM. A comparative study of terbinafine versus griseofulvin in ‘dry-type’ dermatophyte infections. J Am Acad Dermatol. 1991;24(2):243-6.

George M, Chaudhary RG, Rana D, Kasundra D, Chaudhary AR, Malhotra SD, et al. Comparative evaluation of efficacy of terbinafine and itraconazole in treatment of tinea cruris. Int J Basic Clin Pharmacol. 2019;8(7):1460-6.

Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol. 1994;19(2):121-6.

Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005; 1:299-306.